{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:16:30Z","timestamp":1794935790999,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13281-y","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:25:54Z","timestamp":1776133554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Vaccine effectiveness across the Omicron evolutionary spectrum (BA.2, BA.5, XBB, JN.1, KP.3): a systematic review of studies published 2022\u20132025"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-4513","authenticated-orcid":false,"given":"Saad","family":"Alhumaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Alkhars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer S.","family":"Algrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourah Al","family":"Dossary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Elhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab Abbas","family":"Majzoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamela A.","family":"Turkistani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah Mohammed","family":"Alhumaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan Ahmad Al","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aldiaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Hussain","family":"Alahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salamah A.","family":"Alomran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Bassam","family":"AlQatifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Jamal","family":"Alkolib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muath Saleh","family":"Almubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Al-Helal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali J.","family":"Alhaddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain Ahmed","family":"Alsouaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlam Ayesh","family":"Albahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Aldera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadhah Mohammed","family":"Alnasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif","family":"Alhmeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtadha Sameer","family":"Alsulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Al Alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Header A.","family":"Alghazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"13281_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","volume":"399","author":"T Nyberg","year":"2022","unstructured":"Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, Hinsley W, Bernal JL, Kall M, Bhatt S, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399:1303\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(22)00462-7.","journal-title":"Lancet"},{"key":"13281_CR2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O\u2019Connell AM, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386:1532\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2119451.","journal-title":"N Engl J Med"},{"key":"13281_CR3","doi-asserted-by":"publisher","first-page":"2335052","DOI":"10.1080\/21645515.2024.2335052","volume":"20","author":"BK Ackerson","year":"2024","unstructured":"Ackerson BK, Bruxvoort KJ, Qian L, Sy LS, Qiu S, Tubert JE, Lee GS, Ku JH, Florea A, Luo Y, et al. Effectiveness and durability of mRNA-1273 BA.4\/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4\/BA.5 and XBB sublineages. Hum Vaccin Immunother. 2024;20:2335052. https:\/\/doi.org\/10.1080\/21645515.2024.2335052.","journal-title":"Hum Vaccin Immunother"},{"key":"13281_CR4","doi-asserted-by":"publisher","first-page":"e075286","DOI":"10.1136\/bmj-2022-075286","volume":"382","author":"NW Andersson","year":"2023","unstructured":"Andersson NW, Thiesson EM, Baum U, Pihlstr\u00f6m N, Starrfelt J, Faksov\u00e1 K, Poukka E, Meijerink H, Ljung R, Hviid A. Comparative effectiveness of bivalent BA.4\/BA.5 and BA. 1 mRNA booster vaccines among adults aged\u2009\u2265\u200950 years in Nordic countries: nationwide cohort study. BMJ. 2023;382:e075286. https:\/\/doi.org\/10.1136\/bmj-2022-075286.","journal-title":"BMJ"},{"key":"13281_CR5","doi-asserted-by":"publisher","first-page":"e001074","DOI":"10.1136\/bmjmed-2024-001074","volume":"3","author":"NW Andersson","year":"2024","unstructured":"Andersson NW, Thiesson EM, Pihlstrom N, Perala J, Faksova K, Gram MA, Poukka E, Leino T, Ljung R, Hviid A. Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data. BMJ Med. 2024;3:e001074. https:\/\/doi.org\/10.1136\/bmjmed-2024-001074.","journal-title":"BMJ Med"},{"key":"13281_CR6","doi-asserted-by":"publisher","first-page":"e70081","DOI":"10.1111\/irv.70081","volume":"19","author":"L Antunes","year":"2025","unstructured":"Antunes L, Rojas-Castro M, Lozano M, Mart\u00ednez\u2010Baz I, Leroux\u2010Roels I, Borg ML, Oroszi B, Fitzgerald M, D\u00fcrrwald R, Jancoriene L. Effectiveness of the XBB. 1.5 COVID\u201019 Vaccines Against SARS\u2010CoV\u20102 Hospitalisation Among Adults Aged\u2009\u2265\u200965 Years During the BA. 2.86\/JN. 1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza Other Respir Viruses. 2025;19:e70081. https:\/\/doi.org\/10.1111\/irv.70081.","journal-title":"Influenza Other Respir Viruses"},{"key":"13281_CR7","doi-asserted-by":"publisher","first-page":"127752","DOI":"10.1016\/j.vaccine.2025.127752","volume":"64","author":"J Humphreys","year":"2025","unstructured":"Humphreys J, Blake A, Nicolay N, Braeye T, Van Evercooren I, Hansen CH, Moustsen-Helms IR, Sacco C, Mateo-Urdiales A, Castilla J. Effectiveness of JN. 1 monovalent COVID-19 vaccination in EU\/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study. Vaccine. 2025;64:127752. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127752.","journal-title":"Vaccine"},{"key":"13281_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/infdis\/jiad419","volume":"229","author":"R Grewal","year":"2024","unstructured":"Grewal R, Buchan SA, Nguyen L, Nasreen S, Austin PC, Brown KA, Gubbay J, Lee N, Schwartz KL, Tadrous M. Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged\u2009\u2265\u200950 years in Ontario, Canada: A Canadian immunization research network study. J Infect Dis. 2024;229:394\u20137. https:\/\/doi.org\/10.1093\/infdis\/jiad419.","journal-title":"J Infect Dis"},{"key":"13281_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(25)00380-9","volume":"25","author":"CH Hansen","year":"2025","unstructured":"Hansen CH, Lassauniere R, Rasmussen M, Moustsen-Helms IR, Valentiner-Branth P. Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study. Lancet Infect Dis. 2025;25:1293\u2013302. https:\/\/doi.org\/10.1016\/S1473-3099(25)00380-9.","journal-title":"Lancet Infect Dis"},{"key":"13281_CR10","doi-asserted-by":"publisher","first-page":"e2517402","DOI":"10.1001\/jamanetworkopen.2025.17402","volume":"8","author":"R Link-Gelles","year":"2025","unstructured":"Link-Gelles R, Rowley EAK, Irving SA, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva MB, Dascomb K, Naleway AL, et al. Estimated 2023\u20132024 COVID-19 Vaccine Effectiveness in Adults. JAMA Netw Open. 2025;8:e2517402. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.17402.","journal-title":"JAMA Netw Open"},{"key":"13281_CR11","doi-asserted-by":"publisher","first-page":"112097","DOI":"10.1016\/j.jtbi.2025.112097","volume":"605","author":"A Ghosh","year":"2025","unstructured":"Ghosh A, Das P, Chakraborty T, Das P, Ghosh D. Developing cholera outbreak forecasting through qualitative dynamics: Insights into Malawi case study. J Theor Biol. 2025;605:112097. https:\/\/doi.org\/10.1016\/j.jtbi.2025.112097.","journal-title":"J Theor Biol"},{"key":"13281_CR12","doi-asserted-by":"publisher","first-page":"111225","DOI":"10.1016\/j.compbiomed.2025.111225","volume":"198","author":"A Ghosh","year":"2025","unstructured":"Ghosh A, Das P, Das SK, Das P, Upadhyay RK. Forecasting tuberculosis through mechanistic learning of transmission dynamics: Insights from a case study in India. Comput Biol Med. 2025;198:111225. https:\/\/doi.org\/10.1016\/j.compbiomed.2025.111225.","journal-title":"Comput Biol Med"},{"key":"13281_CR13","doi-asserted-by":"publisher","first-page":"127870","DOI":"10.1016\/j.vaccine.2025.127870","volume":"67","author":"N Abdul Aziz","year":"2025","unstructured":"Abdul Aziz N, Kirsebom FCM, Allen A, Andrews N. Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England. Vaccine. 2025;67:127870. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127870.","journal-title":"Vaccine"},{"key":"13281_CR14","doi-asserted-by":"publisher","first-page":"e0325269","DOI":"10.1371\/journal.pone.0325269","volume":"20","author":"S Carazo","year":"2025","unstructured":"Carazo S, Skowronski DM, Brousseau N, Guay CA, Sauvageau C, Racine E, Talbot D, Ionescu IG, Fafard J, Gilca R, et al. Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up. PLoS ONE. 2025;20:e0325269. https:\/\/doi.org\/10.1371\/journal.pone.0325269.","journal-title":"PLoS ONE"},{"key":"13281_CR15","doi-asserted-by":"publisher","first-page":"e70198","DOI":"10.1111\/irv.70198","volume":"19","author":"J Humphreys","year":"2025","unstructured":"Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Hansen CH, Moustsen-Helms IR, Sacco C, Fabiani M, Castilla J, Martinez-Baz I, et al. Effectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU\/EEA: A VEBIS Electronic Health Record Network Study. Influenza Other Respir Viruses. 2025;19:e70198. https:\/\/doi.org\/10.1111\/irv.70198.","journal-title":"Influenza Other Respir Viruses"},{"key":"13281_CR16","doi-asserted-by":"publisher","first-page":"127300","DOI":"10.1016\/j.vaccine.2025.127300","volume":"60","author":"N Lee","year":"2025","unstructured":"Lee N, Nguyen L, Nasreen S, Austin PC, Brown KA, Buchan SA, Grewal R, Schwartz KL, Tadrous M, Wilson K. Limited durability of protection conferred by XBB. 1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults. Ont Can Vaccine. 2025;60:127300. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127300.","journal-title":"Ont Can Vaccine"},{"key":"13281_CR17","doi-asserted-by":"publisher","first-page":"106177","DOI":"10.1016\/j.jinf.2024.106177","volume":"89","author":"FCM Kirsebom","year":"2024","unstructured":"Kirsebom FCM, Stowe J, Lopez Bernal J, Allen A, Andrews N. Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study. J Infect. 2024;89:106177. https:\/\/doi.org\/10.1016\/j.jinf.2024.106177.","journal-title":"J Infect"},{"key":"13281_CR18","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14760584.2024.2428800","volume":"23","author":"B Nunes","year":"2024","unstructured":"Nunes B, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Moustsen-Helms IR, Sacco C, Fabiani M, Castilla J. Monovalent XBB. 1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA. 2.86\/JN. 1 period among older adults in seven European countries: A VEBIS-EHR network study. Expert Rev Vaccines. 2024;23:1085\u201390. https:\/\/doi.org\/10.1080\/14760584.2024.2428800.","journal-title":"Expert Rev Vaccines"},{"key":"13281_CR19","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1056\/NEJMc2302462","volume":"388","author":"DY Lin","year":"2023","unstructured":"Lin DY, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z. Durability of Bivalent Boosters against Omicron Subvariants. N Engl J Med. 2023;388:1818\u201320. https:\/\/doi.org\/10.1056\/NEJMc2302462.","journal-title":"N Engl J Med"},{"key":"13281_CR20","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1038\/s41467-022-30895-3","volume":"13","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Al-Kanaani Z, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun. 2022;13:3082. https:\/\/doi.org\/10.1038\/s41467-022-30895-3.","journal-title":"Nat Commun"},{"key":"13281_CR21","doi-asserted-by":"publisher","first-page":"ofac138","DOI":"10.1093\/ofid\/ofac138","volume":"9","author":"MM Higdon","year":"2022","unstructured":"Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, Nande AA, ShamaeiZadeh PA, Walter KK, Feikin DR. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. Open Forum Infect Dis. 2022;9:ofac138. https:\/\/doi.org\/10.1093\/ofid\/ofac138.","journal-title":"Open Forum Infect Dis"},{"key":"13281_CR22","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.vaccine.2023.02.020","volume":"41","author":"DR Feikin","year":"2023","unstructured":"Feikin DR, Higdon MM, Andrews N, Collie S, Deloria Knoll M, Kwong JC, Link-Gelles R, Pilishvili T, Patel MK. Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization. Vaccine. 2023;41:2329\u201338. https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.020.","journal-title":"Vaccine"},{"key":"13281_CR23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"13281_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/emermed-2020-209567","volume":"37","author":"M Amir-Behghadami","year":"2020","unstructured":"Amir-Behghadami M, Janati A, Population. Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37:387\u201392. https:\/\/doi.org\/10.1136\/emermed-2020-209567.","journal-title":"Emerg Med J"},{"key":"13281_CR25","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"13281_CR26","doi-asserted-by":"publisher","first-page":"126881","DOI":"10.1016\/j.vaccine.2025.126881","volume":"52","author":"KM Andersen","year":"2025","unstructured":"Andersen KM, Allen KE, Nepal RM, Mateus JS, Yu T, Zhou A, Porter TM, Lopez SMC, Puzniak L, McLaughlin JM, McGrath LJ. Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states. Vaccine. 2025;52:126881. https:\/\/doi.org\/10.1016\/j.vaccine.2025.126881.","journal-title":"Vaccine"},{"key":"13281_CR27","doi-asserted-by":"publisher","first-page":"2300708","DOI":"10.2807\/1560-7917.ES.2024.29.3.2300708","volume":"29","author":"L Antunes","year":"2024","unstructured":"Antunes L, Mazagatos C, Martinez-Baz I, Gomez V, Borg ML, Petrovic G, Duffy R, Dufrasne FE, Durrwald R, Lazar M, et al. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged\u2009\u2265\u200960 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023. Euro Surveill. 2024;29:2300708. https:\/\/doi.org\/10.2807\/1560-7917.ES.2024.29.3.2300708.","journal-title":"Euro Surveill"},{"key":"13281_CR28","doi-asserted-by":"publisher","first-page":"e13360","DOI":"10.1111\/irv.13360","volume":"18","author":"L Antunes","year":"2024","unstructured":"Antunes L, Mazagatos C, Mart\u00ednez-Baz I, Naesens R, Borg ML, Petrovi\u0107 G, Fatukasi T, Jancoriene L, Machado A, Oroszi B. Early COVID\u201019 XBB. 1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023\u2013January 2024. Influenza Other Respir Viruses. 2024;18:e13360. https:\/\/doi.org\/10.1111\/irv.13360.","journal-title":"Influenza Other Respir Viruses"},{"key":"13281_CR29","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1038\/s41467-024-53842-w","volume":"15","author":"AR Caffrey","year":"2024","unstructured":"Caffrey AR, Appaneal HJ, Lopes VV, Puzniak L, Zasowski EJ, Jodar L, LaPlante KL, McLaughlin JM. Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System. Nat Commun. 2024;15:9490. https:\/\/doi.org\/10.1038\/s41467-024-53842-w.","journal-title":"Nat Commun"},{"key":"13281_CR30","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1016\/j.vaccine.2024.05.067","volume":"42","author":"CL Delaunay","year":"2024","unstructured":"Delaunay CL, Melo A, Maurel M, Mazagatos C, Goerlitz L, O\u2019Donnell J, Oroszi B, S\u00e8ve N, Rodrigues AP, Mart\u00ednez-Baz I. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023\u2013January 2024. Vaccine. 2024;42:3931\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.067.","journal-title":"Vaccine"},{"key":"13281_CR31","doi-asserted-by":"publisher","first-page":"ofae695","DOI":"10.1093\/ofid\/ofae695","volume":"11","author":"H Kopel","year":"2024","unstructured":"Kopel H, Araujo AB, Bogdanov A, Zeng N, Winer I, Winer-Jones JP, Lu T, Marks MA, Bonafede M, Nguyen VH. Effectiveness of the 2023\u20132024 Omicron XBB. 1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19\u2013related hospitalizations and medical encounters among adults in the United States. Open Forum Infect Dis. 2024;11:ofae695. https:\/\/doi.org\/10.1093\/ofid\/ofae695.","journal-title":"Open Forum Infect Dis"},{"key":"13281_CR32","doi-asserted-by":"publisher","first-page":"107249","DOI":"10.1016\/j.ijid.2024.107249","volume":"148","author":"JA Lee","year":"2024","unstructured":"Lee JA, Jang H, Ahn SM, Seong JE, Kim YK, Sohn Y, Jung SI, Jeong HW, Kim S-W, Lee J-S. Estimates of vaccine effectiveness of the updated monovalent XBB. 1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea-October 26 to December 31, 2023. Int J Infect Dis. 2024;148:107249. https:\/\/doi.org\/10.1016\/j.ijid.2024.107249.","journal-title":"Int J Infect Dis"},{"key":"13281_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae405","author":"KC Ma","year":"2024","unstructured":"Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, Gaglani M, Columbus C, Gottlieb RL, Ghamande S. Effectiveness of updated 2023\u20132024 (monovalent XBB. 1.5) COVID-19 vaccination against SARS-CoV-2 Omicron XBB and BA. 2.86\/JN. 1 lineage hospitalization and a comparison of clinical severity\u2014IVY Network, 26 hospitals, 18 October 2023\u20139 March 2024. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae405. ciae405.","journal-title":"Clin Infect Dis"},{"key":"13281_CR34","doi-asserted-by":"publisher","first-page":"e13292","DOI":"10.1111\/irv.13292","volume":"18","author":"S Monge","year":"2024","unstructured":"Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Emborg HD, Sacco C, Mateo-Urdiales A, Castilla J, et al. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU\/EEA Countries, October to November 2023: A VEBIS-EHR Network Study. Influenza Other Respir Viruses. 2024;18:e13292. https:\/\/doi.org\/10.1111\/irv.13292.","journal-title":"Influenza Other Respir Viruses"},{"key":"13281_CR35","doi-asserted-by":"publisher","first-page":"102995","DOI":"10.1016\/j.eclinm.2024.102995","volume":"79","author":"JL Nguyen","year":"2025","unstructured":"Nguyen JL, Mitratza M, Volkman HR, de Munter L, Tran TMP, Marques C, Mustapha M, Valluri S, Yang J, Anton A, et al. Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform. EClinicalMedicine. 2025;79:102995. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102995.","journal-title":"EClinicalMedicine"},{"key":"13281_CR36","doi-asserted-by":"publisher","first-page":"127275","DOI":"10.1016\/j.vaccine.2025.127275","volume":"59","author":"E Nham","year":"2025","unstructured":"Nham E, Song JY, Sohn JW, Choi WS, Wie SH, Lee J, Lee JS, Jeong HW, Eom JS, Choi YJ, et al. Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months. Vaccine. 2025;59:127275. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127275.","journal-title":"Vaccine"},{"key":"13281_CR37","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1080\/14760584.2025.2576243","volume":"24","author":"A Rojas-Benedicto","year":"2025","unstructured":"Rojas-Benedicto A, Perez-Gimeno G, Mendioroz J, Pedrosa Corral I, Lopez Torrijos M, Rumayor M, Rafael de la Cruz Lopez MA, Rivas Wagner E, Valcarcel de Laiglesia M, Guiu Canete I, et al. Effectiveness of the autumnal COVID-19 vaccine dose during the winter and summer waves of the 2023\/24 season in Spain. Expert Rev Vaccines. 2025;24:980\u201390. https:\/\/doi.org\/10.1080\/14760584.2025.2576243.","journal-title":"Expert Rev Vaccines"},{"key":"13281_CR38","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamainternmed.2024.1640","volume":"184","author":"SY Tartof","year":"2024","unstructured":"Tartof SY, Slezak JM, Frankland TB, Puzniak L, Hong V, Ackerson BK, Stern JA, Zamparo J, Simmons S, Jodar L, McLaughlin JM. Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19. JAMA Intern Med. 2024;184:932\u201340. https:\/\/doi.org\/10.1001\/jamainternmed.2024.1640.","journal-title":"JAMA Intern Med"},{"key":"13281_CR39","doi-asserted-by":"publisher","first-page":"ofae370","DOI":"10.1093\/ofid\/ofae370","volume":"11","author":"SY Tartof","year":"2024","unstructured":"Tartof SY, Slezak JM, Puzniak L, Frankland TB, Ackerson BK, Jodar L, McLaughlin JM. Effectiveness of BNT162b2 XBB vaccine against XBB and JN. 1 sublineages. Open Forum Infect Dis. 2024;11:ofae370. https:\/\/doi.org\/10.1093\/ofid\/ofae370.","journal-title":"Open Forum Infect Dis"},{"key":"13281_CR40","doi-asserted-by":"publisher","first-page":"2300703","DOI":"10.2807\/1560-7917.ES.2024.29.1.2300703","volume":"29","author":"CH van Werkhoven","year":"2024","unstructured":"van Werkhoven CH, Valk AW, Smagge B, de Melker HE, Knol MJ, Hahne SJ, van den Hof S, de Gier B. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023. Euro Surveill. 2024;29:2300703. https:\/\/doi.org\/10.2807\/1560-7917.ES.2024.29.1.2300703.","journal-title":"Euro Surveill"},{"key":"13281_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40121-024-01091-1","volume":"14","author":"A Wilson","year":"2025","unstructured":"Wilson A, Rahai N, Beck E, Beebe E, Conroy B, Esposito D, Govil P, Kopel H, Lu T, Mansi J. Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged\u2009\u2265\u200918 Years in the United States. Infect Dis Therapy. 2025;14:199\u2013216. https:\/\/doi.org\/10.1007\/s40121-024-01091-1.","journal-title":"Infect Dis Therapy"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13281-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13281-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13281-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T03:00:57Z","timestamp":1779678057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13281-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13281"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13281-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1014"}}